Literature DB >> 21492908

Epidemiology of venous thromboembolism in children with malignant diseases: a single-center study of the Belarusian Center for Pediatric Oncology and Hematology.

Natalie V Lipay1, Anfisa I Zmitrovich, Olga V Aleinikova.   

Abstract

BACKGROUND: Venous thrombosis is a complication of treatment of children with cancer but studies devoted to the epidemiology of thrombosis in children with cancer are rare and data are scanty.
OBJECTIVE: To determine the prevalence and clinical characteristics of VT as a secondary complication in children with malignant disease and to estimate the ten-year experience of our hospital.
METHOD: Retrospective analysis of data of Children's Cancer Subregistry of Belarus, which included information about age, gender, details of diagnosis, classification of malignant neoplasm according to ICD-10, treatment protocol and outcome. Clinical information was obtained from case histories.
RESULTS: For the specified period, 2061 children with newly diagnosed cancer and 44 cases of VT have been registered. Among VT cases, hematological malignancies prevailed (32 of total 44). Higher incidence of VT in AML and APL groups was shown (p‹0.05). In patients with VT, boys (M/F = 1,6/1) and teenagers prevailed (65,9%). Of 44 patients, 33 had catheter-associated thrombosis (CAT). Almost all CAT (91,7%) were in the upper venous system. Children with non-CAT (11 out of 44) had more prolonged duration of immobilization, than children with CAT (p‹0.05) and in this group, thrombosis affected predominantly the lower limb (9 out of 11).
CONCLUSION: The present study has shown that venous thrombosis occurs significantly more often in children with AML and APL. Prevalence of boys in patients with venous thrombosis has been noted. Increased frequency of VT events in teenagers has been observed and the provoking role of CVC and immobilization for thrombosis has been confirmed.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21492908     DOI: 10.1016/j.thromres.2011.03.014

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

Review 1.  Global characteristics of childhood acute promyelocytic leukemia.

Authors:  L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer
Journal:  Blood Rev       Date:  2014-09-30       Impact factor: 8.250

2.  The association of mediastinal mass in the formation of thrombi in pediatric patients with non-lymphoblastic lymphomas.

Authors:  Jessica Gartrell; Sue C Kaste; John T Sandlund; Jamie Flerlage; Yinmei Zhou; Cheng Cheng; Jeremie Estepp; Monika L Metzger
Journal:  Pediatr Blood Cancer       Date:  2019-11-17       Impact factor: 3.167

Review 3.  Challenges in Management of VTE in Children With Cancer: Risk Factors and Treatment Options.

Authors:  Nasrin Samji; Mihir D Bhatt; Ketan Kulkarni
Journal:  Front Pediatr       Date:  2022-04-07       Impact factor: 3.569

4.  Venous thromboembolism in children with cancer - a population-based cohort study.

Authors:  Alex J Walker; Matthew J Grainge; Tim R Card; Joe West; Susanna Ranta; Jonas F Ludvigsson
Journal:  Thromb Res       Date:  2013-12-21       Impact factor: 3.944

Review 5.  Venous Thromboembolism in Children with Cancer and Blood Disorders.

Authors:  Richard H Ko; Courtney D Thornburg
Journal:  Front Pediatr       Date:  2017-02-06       Impact factor: 3.418

6.  Venous Thromboembolism in Children and Young Adults in Korea: Analysis of the Korean Health Insurance Review and Assessment Service Database.

Authors:  Eun Sil Park; Hyoung Soo Choi; Kyeong Soo Lee; Sang Won Kim; Jae Min Lee
Journal:  J Korean Med Sci       Date:  2019-12-23       Impact factor: 2.153

7.  Thrombosis and Anticoagulant Therapy Among Pediatric Cancer Patients: Real-Life Data.

Authors:  Hasan Hashem; Momen Zeineddin; Rayan Bater; Nisreen Amayiri; Wiam Al Qasem; Bilasan Hammo; Iyad Sultan; Rama AlMasri; Hikmat Abdel-Razeq
Journal:  Cureus       Date:  2021-12-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.